* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Beximco Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a Days Payable of 32.66 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beximco Pharmaceuticals and its competitors. This is 67% above median its historical median of 19.50. Over the past decade, Beximco Pharmaceuticals' Days Payable has ranged from 11.65 to 24.86.
Is Beximco Pharmaceuticals' Days Payable too high?
Beximco Pharmaceuticals' current Days Payable of 32.66 is 67% above median its 10-year median of 19.50. Over the past 10 years, this metric has ranged from a low of 11.65 to a high of 24.86. The Drug Manufacturers industry median Days Payable is 90.84. Beximco Pharmaceuticals' value of 32.66 is 64% below this industry median. Overall, Beximco Pharmaceuticals has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Days Payable compare to ZTS and UTHR?
Beximco Pharmaceuticals' Days Payable of 32.66 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 90.84. Beximco Pharmaceuticals' value of 32.66 is 64% below this benchmark. Historically, Beximco Pharmaceuticals' own Days Payable has ranged from 11.65 to 24.86 over the past decade. While the company's 10-year median is 19.50 vs. the industry median of 90.84, Beximco Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Days Payable of 32.66 is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Days Payable is 32.66, which is 67% above median its own 10-year median of 19.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Days Payable of 32.66. The current Days Payable is 32.66, which is 67% above median its 10-year median of 19.50 and 64% below the Drug Manufacturers industry median of 90.84. Beximco Pharmaceuticals' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Days Payable is 32.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 